ProCE Banner Activity

ASSURE: Dose Reduction of Sunitinib or Sorafenib Not Associated With Improved Outcomes in Resected RCC

Slideset Download
Conference Coverage
Results of a dose amendment to the phase III ASSURE trial; impact on safety and clinical outcome discussed.

Released: June 04, 2015

Expiration: June 02, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation